The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Epoetin biosimilars in the management of anemia secondary to chemotherapy in patients with solid tumors, lymphomas, and myelomas: The ORHEO study.
Elisabeth Luporsi-Gely
No relevant relationships to disclose
Pierre-Louis Soubeyran
Consultant or Advisory Role - Hospira (U); Janssen (U); Roche (U)
Honoraria - Hospira; Janssen; Roche
Mauricette Michallet
Consultant or Advisory Role - Hospira (U)